What is the recommended daily dose of bempedoic acid for a patient with established cardiovascular disease (CVD) and elevated Low-Density Lipoprotein Cholesterol (LDL-C) despite maximally tolerated statin therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Daily Dose of Bempedoic Acid

The recommended daily dose of bempedoic acid is 180 mg taken orally once daily, with or without food. 1, 2, 3

Standard Dosing Protocol

  • Take 180 mg orally once daily as a single dose, which can be administered with or without food. 1, 2, 3

  • The tablet must be swallowed whole and should not be crushed or split. 2

  • No dose adjustment is required based on LDL-C response—the dose remains fixed at 180 mg daily regardless of lipid levels achieved. 2

Combination Therapy Dosing

  • When using the fixed-dose combination product with ezetimibe, take one tablet containing 180 mg bempedoic acid plus 10 mg ezetimibe once daily. 1, 2

  • If combining with bile acid sequestrants, administer bempedoic acid either 2 hours before or 4 hours after the bile acid sequestrant to avoid binding interactions. 2

Critical Dosing Restrictions with Statins

  • Do not exceed simvastatin 20 mg daily when used concomitantly with bempedoic acid due to increased statin exposure risk. 1, 2

  • Do not exceed pravastatin 40 mg daily when used concomitantly with bempedoic acid due to increased statin exposure risk. 1, 2

  • No dose restrictions apply when combining bempedoic acid with other statins (atorvastatin, rosuvastatin, etc.). 1

Special Population Considerations

  • No dosage adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B). 3

  • Patients with severe hepatic impairment (Child-Pugh C) have not been studied, so use caution in this population. 3

  • No renal dose adjustment is required, though bempedoic acid exposure increases 1.5-fold in mild renal impairment, 2.3-fold in moderate impairment, and 2-fold in severe impairment. 3

Mandatory Safety Monitoring

  • Assess serum uric acid levels before initiating therapy and monitor if symptoms of hyperuricemia develop, as bempedoic acid increases uric acid by a mean of 0.8 mg/dL. 1, 2, 4

  • Monitor for signs and symptoms of tendinitis or tendon rupture; discontinue immediately if tendon rupture occurs. 1, 2

  • Monitor liver function tests as clinically indicated, particularly at baseline and periodically during treatment. 5, 2

Common Pitfalls to Avoid

  • Do not attempt to titrate the dose based on LDL-C response—180 mg daily is the only approved dose. 2

  • Do not combine with high-dose simvastatin (>20 mg) or pravastatin (>40 mg) as this significantly increases statin exposure and toxicity risk. 1, 2

  • Do not discontinue monitoring for hyperuricemia, as gout occurs in 1.5% of patients on bempedoic acid versus 0.4% on placebo. 6, 7

References

Guideline

Bempedoic Acid Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Role of Bempedoic Acid in Clinical Practice.

Cardiovascular drugs and therapy, 2021

Guideline

Intensifying Lipid-Lowering Therapy in High-Risk Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Hypercholesterolemia with Bempedoic Acid and Repatha

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended treatment for patients with hypercholesterolemia who require additional low-density lipoprotein (LDL) cholesterol lowering beyond statins, using bempedoic acid (Nexletol) and Repatha (evolocumab)?
Should bempedoic acid be used for primary prevention in adults without ASCVD but with high estimated 10‑year cardiovascular risk who cannot achieve LDL‑C targets with lifestyle measures, maximally tolerated statin therapy, and ezetimibe?
What is the recommended dose of bempedoic acid (Bempedoic acid) for a patient with hyperlipidemia?
What are the indications, dosing, monitoring requirements, and contraindications for bempedoic acid?
Can bempedoic acid be used in chronic kidney disease stage 2 and stage 4, and what is the appropriate dosage?
What is the best course of action for a patient experiencing low libido and extreme fatigue while taking Buspar (buspirone), Wellbutrin (bupropion), and Zoloft (sertraline)?
How does Zetia (ezetimibe) help reduce cardiovascular risk in patients where hypercholesterolemia is not the primary driving factor for their condition?
What is the recommended dosage of amoxicillin (bid vs tid) for a patient with strep throat, considering factors such as age, weight, medical history, and history of antibiotic allergies or sensitivities?
What antibiotics are recommended for a patient with diphtheria?
What is electrical alternans and how is it managed in patients with suspected cardiac tamponade, ventricular tachycardia, or severe heart failure?
Can bupropion (Wellbutrin) affect vision in patients, particularly those with pre-existing visual disturbances or taking high doses?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.